Navigation Links
AtheroNova to Present at the 2013 Aegis Healthcare Conference in Las Vegas
Date:9/19/2013

ts are based upon the current beliefs and expectations of AtheroNova's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; AtheroNova's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of AtheroNova's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

AtheroNova undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in AtheroNova's 2012 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).


'/>"/>
SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
2. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
3. AtheroNova Announces a New Board Member
4. AtheroNova Achieves Milestone in Initiating First Shipment of AHRO-001
5. AtheroNova Releases 2011 Financial Results
6. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
7. AtheroNova Names New Director
8. AtheroNova Receives Notice of Issuance of Its U.S. Patent 8,304,383
9. AtheroNova Adds New Medical Advisor
10. Noted Atherosclerosis Researcher Joins AtheroNova Team
11. AtheroNova Announces Approval for Phase 1 by the Russian Ministry of Healthcare with Commencement of Human Trials Imminent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)...  BioNano Genomics, Inc., the leader in genome mapping, ... chief commercial officer. Salyer has more than 20 years ... life sciences. At BioNano, Salyer will oversee the commercialization ... to assemble a comprehensive view of complex genomes to ... institutions located in the United States ...
(Date:3/26/2015)... ReliantHeart, Inc., an innovative supplier of advanced ... precision transit-time flow measurement solutions, are collaborating on a ... of the HeartAssist5® Left Ventricular Assist Device ... mobility and peace of mind. , The Transonic ... draw 1/6th of the power required by earlier flow ...
(Date:3/25/2015)... market is one of the most attractive in the ... plus a growing economy and increasing government investment in ... The Russian market is set to grow at twice ... estimates around 10-15% annually reaching an approximate market value ... Cross Green Cross provides total healthcare solutions ...
(Date:3/25/2015)... March 25, 2015 The surging ... smartphones have fuelled social media growth, with over ... engaged in social networking. Insurance companies are making ... with clients and promote a diversity of their ... are increasingly exploiting social networking services as part ...
Breaking Biology Technology:BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 2Social Media Role in Global Insurance Industry Examined by Timetric in New Market Research Report Published at MarketPublishers.com 3
... Calif., Oct. 3 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... be webcast live during the 4th Annual BIO ... p.m. Eastern Time. The presentation,will be webcast from ... accessed,under the Investor Relations tab at http://www.alexza.com ...
... enhance equity stake in Zenotech Laboratories to 45%, ... Zenotech Laboratories Limited (Zenotech) today announced the,signing of Definitive ... from its current 7% to 45% at a price ... This involves: (a) Purchase of shares from the ...
... Marshall Edwards,Inc. (Nasdaq: MSHL ) will present ... Palace Hotel on Thursday, October 11, 2007 at 12:00 ... Inc. (Nasdaq: MSHL ) is a specialist oncology ... derive from a flavonoid technology platform which has generated ...
Cached Biology Technology:The 4th Annual BIO Investor Forum to Webcast Alexza's Corporate Presentation 2Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology 2Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology 3Marshall Edwards, Inc. to Present at BIO Investor Forum 2007 2Marshall Edwards, Inc. to Present at BIO Investor Forum 2007 3
(Date:3/11/2015)... BOSTON , March 11, 2015   ... of its platform to scientifically measure and harness ... characteristics to real-time biometrics and objective measurements of ... of music at scale in large populations. It ... scientists, technologists and clinicians perform rigorous studies and ...
(Date:3/10/2015)... March 10, 2015 Transforming How ... "Personalized Medicine in Human Space Flight" by ... J. Goodwin , Ph.D. was recently featured by Springer ... two years. Specifically, "Personalized Medicine in Human ... papers published in 2013 and 2014 from Springer in ...
(Date:3/10/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ... biometric authentication company focused on the growing mobile ... has been named the "Number One Best Tech ... Rethink Modern ( http://www.rethinkmodern.com/ ) is a web ... and lifestyle that have a unique function or design.  ...
Breaking Biology News(10 mins):Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4
... robot named Eliza to conquer the tyranny of distance and ... , Eliza, who began work at Mt Isa Hospital this ... Health ?a world leader in telemedicine research. , ... sick children for video-link consultations with Brisbane specialists, greatly reducing ...
... are using genetic studies and natural chemicals, such as ... and early molecular interactions can lead to cancer, and ... off a variety of cancers. The latest studies with ... American Association for Cancer Research's Frontiers in Cancer Prevention ...
... for costly insulin injections for diabetics, regenerating heart muscle ... engineering immune cells top a list of 10 potential ... the new world of regenerative medicine, according to a ... of Science (PLoS) Medicine. , Conducted by University of ...
Cached Biology News:Telemedicine robots help improve health 2Plant-derived molecules, genetic manipulation point to future chemoprevention methods 2Plant-derived molecules, genetic manipulation point to future chemoprevention methods 3Plant-derived molecules, genetic manipulation point to future chemoprevention methods 4Plant-derived molecules, genetic manipulation point to future chemoprevention methods 5Replacing insulin is top-ranked breakthrough foreseen for health in developing world 2Replacing insulin is top-ranked breakthrough foreseen for health in developing world 3Replacing insulin is top-ranked breakthrough foreseen for health in developing world 4Replacing insulin is top-ranked breakthrough foreseen for health in developing world 5Replacing insulin is top-ranked breakthrough foreseen for health in developing world 6
...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
Supplemental reagent for annexin V assay....
Large-fragment, single-stranded carrier DNA of the highest quality, perfectly suited for all types of yeast transformation....
Biology Products: